We are a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer. Our cancer-targeted compounds are selectively taken up and retained in cancer cells, including cancer stem cells, versus normal cells. Thus, our therapeutic compounds appear to directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse.
I-124-CLR1404 (LIGHT) is a small-molecule, broad-spectrum, cancer-targeted PET imaging agent. We believe LIGHT has the potential to be the first imaging agent to use proprietary phospholipid ether analogs (PLE) to target cancer cells. Phase 1-2 clinical trials are ongoing across 11 solid tumor indications.
I-131-CLR1404 (HOT) is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. We believe HOT also has first-in-class potential as the first therapeutic agent to use PLEs to target cancer cells. The HOT Phase 1b dose-escalation trial is ongoing as a monotherapy for solid tumors with significant unmet medical need.
CLR1502 (GLOW2) is a preclinical, cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.
CLR1404 (COLD), a pre-clinical cancer-targeted nonradioactive chemotherapy, works primarily through Akt inhibition.
Together, we believe our compounds are able to “find, treat and follow” cancer anywhere in the body in a novel, effective and highly selective way.